127 related articles for article (PubMed ID: 2146258)
21. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
[TBL] [Abstract][Full Text] [Related]
22. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
23. Urokinase mutant with better fibrin-specificity.
Ma Z; Yu R; Hua Z; Zhu D
Sci China C Life Sci; 1996 Oct; 39(5):523-33. PubMed ID: 9772355
[TBL] [Abstract][Full Text] [Related]
24. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
[TBL] [Abstract][Full Text] [Related]
25. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
26. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
[TBL] [Abstract][Full Text] [Related]
27. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
28. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Holmes WE; Collen D
J Biol Chem; 1988 Apr; 263(12):5594-8. PubMed ID: 2965704
[TBL] [Abstract][Full Text] [Related]
29. Enzymatic properties of single-chain and two-chain forms of a Lys158----Glu158 mutant of urokinase-type plasminogen activator.
Lijnen HR; Van Hoef B; Nelles L; Holmes WE; Collen D
Eur J Biochem; 1988 Feb; 172(1):185-8. PubMed ID: 2894309
[TBL] [Abstract][Full Text] [Related]
30. Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects.
Braat EA; Levi M; Bos R; Haverkate F; Lassen MR; de Maat MP; Rijken DC
J Lab Clin Med; 1999 Aug; 134(2):161-7. PubMed ID: 10444030
[TBL] [Abstract][Full Text] [Related]
31. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.
Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC
Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659
[TBL] [Abstract][Full Text] [Related]
32. Activation of thrombin-inactivated single-chain urokinase-type plasminogen activator by dipeptidyl peptidase I (cathepsin C).
Nauland U; Rijken DC
Eur J Biochem; 1994 Jul; 223(2):497-501. PubMed ID: 8055919
[TBL] [Abstract][Full Text] [Related]
33. The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin.
Braat EA; Los P; Rijken DC
Blood Coagul Fibrinolysis; 1998 Jul; 9(5):419-27. PubMed ID: 9712290
[TBL] [Abstract][Full Text] [Related]
34. Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes.
Lee SG; Kalyan N; Wilhelm J; Hum WT; Rappaport R; Cheng SM; Dheer S; Urbano C; Hartzell RW; Ronchetti-Blume M
J Biol Chem; 1988 Feb; 263(6):2917-24. PubMed ID: 3125172
[TBL] [Abstract][Full Text] [Related]
35. Assay method for single-chain urokinase-type plasminogen activator.
Matsuo O; Ueshima S; Okada K; Fukao H; Ohgaki M; Watanabe R; Arimura H
Hematol Pathol; 1989; 3(3):137-42. PubMed ID: 2531734
[TBL] [Abstract][Full Text] [Related]
36. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential.
Lijnen HR; Wnendt S; Schneider J; Janocha E; Van Hoef B; Collen D; Steffens GJ
Eur J Biochem; 1995 Nov; 234(1):350-7. PubMed ID: 8529664
[TBL] [Abstract][Full Text] [Related]
37. A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinase-type plasminogen activator in human body fluids.
Braat EA; Nauland U; Dooijewaard G; Rijken DC
Thromb Haemost; 1996 Jun; 75(6):908-14. PubMed ID: 8822585
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the murine plasminogen/urokinase-type plasminogen-activator system.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1996 Nov; 241(3):840-8. PubMed ID: 8944773
[TBL] [Abstract][Full Text] [Related]
39. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
40. The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator.
Liu JN; Gurewich V
Blood; 1993 Feb; 81(4):980-7. PubMed ID: 8428004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
